Home / Journals Journal of Cancer Treatment and Research / MiRNAs Related with Cancer Drug Resistance
MiRNAs Related with Cancer Drug Resistance
Submission Deadline: Apr. 30, 2015

This special issue currently is open for paper submission and guest editor application.

Join as Guest Editor Submit to Special Issue
Lead Guest Editor
Sercan Ergün
Department of Medical Biology, Faculty of Medicine, Gaziantep University, Sahinbey, Gaziantep, Turkey
Guest Editor
  • Kaifee Arman
    Department of Medical Biology, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey
Guidelines for Submission
Manuscripts can be submitted until the expiry of the deadline. Submissions must be previously unpublished and may not be under consideration elsewhere.
Papers should be formatted according to the guidelines for authors (see: http://www.sciencepublishinggroup.com/journal/guideforauthors?journalid=654). By submitting your manuscripts to the special issue, you are acknowledging that you accept the rules established for publication of manuscripts, including agreement to pay the Article Processing Charges for the manuscripts. Manuscripts should be submitted electronically through the online manuscript submission system at http://www.sciencepublishinggroup.com/login. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal and will be listed together on the special issue website.
Published Papers
The special issue currently is open for paper submission. Potential authors are humbly requested to submit an electronic copy of their complete manuscript by clicking here.
Introduction
Chemotherapy is the preferred treatment for cancer treatment. However, a successful long-term use of chemotherapy is often prevented by the development of drug resistance. Resistance to chemotherapy and molecularly targeted therapies is a major problem facing current cancer research. The anticancer drug resistance mechanisms have been extensively explored, yet have not been fully characterized. Recent works have underlined the involvement of noncoding RNAs in cancer development, with several studies regarding their possible involvement in the evolution of drug resistance. MiRNAs are negative regulators of protein coding genes. Recently, microRNA-122’s functions in breast cancer (BC) remain unknown. During last decades, microRNAs (miRNAs), a class of non-coding RNAs, have emerged as critical players in cancer pathogenesis and progression by modulating many pathological aspects related to tumor development, growth, metastasis, and drug resistance. More recently, accumulating evidence is revealing an important role of miRNAs in anticancer drug resistance and miRNA expression profiling can be correlated with the development of anticancer drug resistance. The micro-RNA-mediated form of drug resistance adds yet another mechanism of drug resistance. So, exploiting the emerging knowledge of miRNAs for the development of new human therapeutic applications for overcoming anticancer drug-resistance will be important. This special issue would include all miRNA involvements which lead to cancer drug resistance.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186